| Registered No. |
Intervention |
Start Year |
Patient |
Phase |
Sponsor |
Status |
| NCT01749865 |
CIK |
2008 |
After radical resection |
III |
Sun Yat-sen University |
Completed |
| NCT00562666 |
Gamma delta T lymphocytes |
2008 |
Non operable tumor |
I |
Rennes University Hospital |
Terminated |
| NCT00699816 |
Immuncell-LC: in vitro activated T cells |
2008 |
Stage of I or II, tumor completely removed by resection |
III |
Green Cross Cell Corporation |
Completed |
| NCT00769106 |
CIK |
2008 |
After radical resection |
III |
Sun Yat-sen University |
Completed |
| NCT01024530 |
IKCs: ex vivo expanded autologous IKCs plus TACE |
2009 |
Never receive TACE treatment |
II/III |
Shin Kong Wu Ho-Su Memorial Hospital |
unknown |
| NCT01147380 |
Liver NK cell inoculation with liver transplantation |
2010 |
Liver transplant recipient with HCC |
I |
Seigo Nishida, University of Miami |
Completed |
| NCT01174121 |
Short-term cultured, autologous TILs |
2010 |
Metastatic HCC standard chemotherapy |
II |
National Cancer Institute (NCI) |
Recruiting |
| NCT01462903 |
Autologous TILs plus IL-2 |
2011 |
Metastatic HCC |
I |
Sun Yat-sen University |
Recruiting |
| NCT01758679 |
CIK and Licartin |
2012 |
Postoperative HCC |
IV |
Tianjin Medical University Cancer Institute and Hospital |
Recruiting |
| NCT01801852 |
Autologous NKT cell infusion |
2013 |
Refractory to conventional treatment |
I |
Chinese PLA General Hospital |
Recruiting |
| NCT02026362 |
CTL induced by DC loaded with multiple antigens |
2013 |
After complete resection |
I |
SYZ Cell Therapy Co. |
Recruiting |
| NCT01821482 |
DCs and CIKs |
2013 |
After complete resection or TACE |
II |
Guangxi Medical University |
Not yet Recruiting |
| NCT01897610 |
Immuncell-LC: activated T cells, with Nexavar |
2013 |
Stage III and IV, Nexavar treated or ready to be treated |
II |
Green Cross Cell Corporation |
Recruiting |
| NCT02008929 |
MG4101: ex vivo expanded allogeneic NK Cell |
2014 |
After curative resection |
II |
Samsung Medical Center |
Recruiting |
| NCT01914263 |
Cord Blood-derived CIKs |
2014 |
After radical resection |
I |
Alliancells-PuRuiBiocience Co., Ltd. |
Recruiting |
| NCT02487017 |
DC-CIK combined with TACE |
2015 |
After TACE treatment |
II |
Shenzhen Hornetcorn Bio-technology Company |
Recruiting |
|
